Infinium Pharmachem share news, announcements and annual reports

NSE: INFINIUMPharmaceuticals & Biotechnology

Infinium Pharmachem Limited · Face value ₹10 · Listed Apr 2023 · Issue price ₹135

₹281.00₹3.00 (1.08%)

Share price at the NSE close on 30 Oct 2026. Previous close ₹278.00.

30 Oct: open ₹285.75, high ₹285.75, low ₹281.00

52-week range of traded prices to 30 Oct 2026

₹189.40Low, 30 Mar 2026₹324.50High, 6 Oct 2026

Next results date: the board meets on 6 Nov 2026 to consider: financial results. The notice · Results calendar

Market cap: ₹438 Cr
P/E: 36.04
P/B: 3.62
Dividend yield: Nonein the last 12 months
ROE: 10.5%
Debt to equity: 0.17
Volume, NSE: 2,500100.0% delivered

Infinium Pharmachem disputes and clarifications

12 filed, newest first.

Apr 2026
- 13 Apr · Legal
  Exchange had sought clarification from Infinium Pharmachem Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: The response of the Company is enclosed.
Jun 2025
- 25 Jun · Legal
  Exchange has sought clarification from Infinium Pharmachem Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI -2. Segment details not submitted The response of the Company is awaited.
Apr 2025
- 25 Apr · Legal
  Significant movement in price has been observed in Infinium Pharmachem Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Dec 2024
- 19 Dec · Legal
  Exchange had sought clarification from Infinium Pharmachem Limited for the quarter ended 30-Sep-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI -2. Segment details not submitted The response of the Company is enclosed.
- 11 Dec · Legal
  Exchange has sought clarification from Infinium Pharmachem Limited for the quarter ended 30-Sep-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI -2. Segment details not submitted The response of the Company is awaited.
Sep 2024
- 20 Sep · Legal
  Significant movement in price has been observed in Infinium Pharmachem Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Jan 2024
- 11 Jan · Legal
  Exchange had sought clarification from Infinium Pharmachem Limited for the quarter ended 30-Sep-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI -2. Segment details not submitted -3. Financial results not signed by authorized signatory/ies The response of the Company is enclosed.
Dec 2023
- 11 Dec · Legal
  Exchange has sought clarification from Infinium Pharmachem Limited for the quarter ended 30-Sep-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI -2. Segment details not submitted -3. Financial results not signed by authorized signatory/ies The response of the Company is awaited.
Nov 2023
- 20 Nov · Legal
  Exchange had sought clarification from Infinium Pharmachem Limited with respect to announcement dated 29-Oct-2023, regarding Appointment of Mr. Nilesh Patel as Company Secretary & Compliance Officer of the company w.e.f. November 20, 2023. On basis of above the Company was required to clarify following: 1. Brief profile (in case of appointment). The response of the Company is attached.
- 8 Nov · Legal
  Exchange has sought clarification from Infinium Pharmachem Limited with respect to announcement dated 29-Oct-2023, regarding Appointment of Mr. Nilesh Patel as Company Secretary & Compliance Officer of the company w.e.f. November 20, 2023. On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment)The response of the Company is awaited.
May 2023
- 26 May · Legal
  Exchange had sought clarification from Infinium Pharmachem Limited for the quarter ended 31-Mar-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Segment details not submitted -2. Financial results submitted is not as per format prescribed by SEBI -3. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is enclosed.
- 23 May · Legal
  Exchange has sought clarification from Infinium Pharmachem Limited for the quarter ended 31-Mar-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI -2. Segment details not submitted -3. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.

Infinium Pharmachem disputes and clarifications

Apr 2026

Jun 2025

Apr 2025

Dec 2024

Sep 2024

Jan 2024

Dec 2023

Nov 2023

May 2023